Tag: PAA
PharmAust subsidiary Epichem to advance ‘world first’ waste-to-fuel conversion technology
PharmAust’s (ASX: PAA) subsidiary Epichem has inked a licencing deal that will see it research, develop and promote a disruptive flow reactor technology that converts waste to fuel.
Thermaquatica f...
PharmAust calls for more dogs for anti-cancer canine drug trial
Biotech company PharmAust (ASX: PAA) has officially begun recruitment for the phase IIb trial of its lead anti-cancer drug monepantel (MPL) on canine lymphoma and has put a call out for more dogs to p...
PharmAust seeks more canine participants for phase IIb lymphoma trial using lead drug monepantel
Biotechnology firm PharmAust (ASX: PAA) is looking to recruit more canines with B-cell lymphoma to a new phase IIb trial evaluating a re-formulation of its lead anti-cancer drug monepantel, which has ...
PharmAust begins next trial using monepantel to treat canines with lymphoma
Following a successful phase IIa trial using monepantel (MPL) to treat canine lymphoma, PharmAust’s (ASX: PAA) phase IIb study has begun.
The recent phase IIa trial using monepantel to treat B-cell...
PharmAust posts strong September quarter led by advances in development of lead drug monepantel
Oncology company PharmAust (ASX: PAA) has posted a strong quarter of business activity, led by a hefty grant last month for a phase 1 clinical trial to investigate the effects of lead drug monepantel ...
Olivia Newton-John Cancer Research Institute evaluates PharmAust’s anti-cancer drug
Clinical-stage oncology company PharmAust (ASX: PAA) has announced the Olivia Newton-John Cancer Research Institute (ONJCRI) is investigating the anti-cancer mechanism of its flagship drug candidate m...
PharmAust advances testing of monepantel drugs against COVID-19
PharmAust (ASX: PAA) is set to test the ability of its monepantel and monepantel sulfone drugs on their ability to inhibit coronavirus SARS-CoV-2 infection, the virus behind the COVID-19 global pandem...
PharmAust receives grant from FightMND for monepantel phase one trial in motor neuron disease
Motor neurone disease (MND) charity FightMND has awarded oncology company PharmAust (ASX: PAA) a grant for a Phase 1 trial to examine the effects of its flagship drug candidate monepantel on the disea...
PharmAust lays out market strategy for lead drug monepantel
Oncology company PharmAust (ASX: PAA) has provided a timely update to the market concerning developments of its lead drug candidate, monepantel (MPL).
PharmAust is currently progressing the drug in...
PharmAust confirms monepantel’s anti-viral potential in fight against COVID-19
Determined to become one of the first companies to develop an active treatment for COVID-19, oncology company PharmAust (ASX: PAA) has reported it has successfully repeated a second round of in-vitro ...
PharmAust subsidiary Epichem signs JV to develop waste-to-fuels technology
PharmAust (ASX: PAA) subsidiary Epichem has entered into a 50:50 joint venture agreement with Western Australia-based private company Obsidian Minerals to develop a novel and disruptive waste-to-fuels...
PharmAust trims losses as monepantel drug development progresses
Oncology company PharmAust (ASX: PAA) has narrowed its losses for the full year as it celebrated many achievements in the overall development of its lead cancer drug, monepantel (MPL).
MPL is a vet...
PharmAust research shows monepantel can inhibit progression of SARS-CoV-2 virus
Preliminary research findings on PharmAust’s (ASX: PAA) lead candidates monepantel and monepantel sulfone have demonstrated that application of the drugs on human respiratory cells can inhibit the pro...
PharmAust clinical trials show monepantel fights COVID-19 infectivity, improves prognosis for canines with cancer
Clinical stage oncology company PharmAust (ASX: PAA) has attributed a successful June quarter performance to lead drug monepantel and monepantel sulfone which has shown “remarkable” early results agai...
Repeat experiment proves PharmAust’s lead cancer drug can reduce infectivity of COVID-19 cells
A repeat preliminary evaluation of PharmAust’s (ASX: PAA) lead cancer drug monepantel and monepantel sulfone has found it can reduce transmission in cells infected with the current SARS-CoV-2 strain o...
Studies show PharmAust’s lead cancer drug could suppress COVID-19 infectivity
Preliminary clinical work by PharmAust (ASX: PAA) on the effects of its lead candidate monepantel and monepantel sulfone on cells infected with COVID-19 has demonstrated potential suppression of the v...
PharmAust makes progress towards next clinical trial of monepantel
Oncology company PharmAust (ASX: PAA) came out of a trading halt this morning with news that its monepantel canine trial achieved a “successful outcome” with phase 3 trials already on the horizon.
...
PharmAust and U-Vet gear up for Phase 2 clinical trial of leading drug candidate monepantel
Oncology company PharmAust (ASX: PAA) is on the home straight to commencing a milestone drug trial following the finalisation of contractual arrangements for its Phase 2 canine cancer trial, to be com...
PharmAust reports positive results from phase I anti-cancer tablet trial on dogs
Clinical-stage oncology company PharmAust (ASX: PAA) has received early positive results from a phase I trial of its reformulated monepantel anti-cancer tablets.
The canine-based trial commenced la...
PharmAust to begin anti-cancer tablet trials in dogs this month
Oncology company PharmAust (ASX: PAA) has manufactured its first batch of monepantel anti-cancer tablets in readiness for the phase I clinical trial in dogs, which will begin later this month.
The ...
PharmAust’s principal metabolite confirmed to have anti-cancer properties
Oncology company PharmAust (ASX: PAA) has revealed positive news in relation to its ongoing development of monepantel, with the company confirming that monepantel’s major metabolite has exhibited anti...
